“Remdesivir for COVID-19” Study accidentally proved effectiveness of Hydroxychloroquine
The use of Remdesivir for COVID-19 was authorized by the FDA based on a single RCT, conducted by NIAID with the participation of Gilead Sciences, the exclusive manufacturer of Remdesivir. A final report from this study was published on October 8, five months after the drug’s authorization.
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed